Add to Watchlist
View Current for AMLX
View SuperFeed for AMLX
View Charts for AMLX
Add or remove $AMLX from your watchlists:
Hang tight! We're updating your watchlist data.
This might take a minute...
Amylyx Pharmaceuticals Inc
Amylyx Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, engages in developing various therapeutics for amyotrophic lateral sclerosi… more
🤔 Insider Trades
$AMLX trades made by insiders of the company, Past 60 days. PRO TIP: Click+Drag your mouse to ZOOM IN!
Select Filters:
Date | Name | Role | Type | Security Name | Amount or # of Shares |
Jan. 6, 2023 | Yeramian Patrick D | Officer: Chief Medical Officer | Buy |
Common Stock | 629 |
Jan. 6, 2023 | Frates James M | Officer: Svp & Cfo, Alkermes Plc | Buy |
Common Stock | 822 |
Jan. 6, 2023 | Klee Justin B. | Director, Officer: Co-Chief Executive Officer | Buy |
Common Stock | 1,846 |
Jan. 6, 2023 | Olinger Margaret | Officer: Chief Commercial Officer | Buy |
Common Stock | 743 |
Jan. 6, 2023 | Cohen Joshua B | Director, Officer: Co-Chief Executive Officer | Buy |
Common Stock | 1,846 |
Jan. 6, 2023 | Klee Justin B. | Director, Officer: Co-Chief Executive Officer | Buy |
Common Stock | 4,122 |
Jan. 6, 2023 | Yeramian Patrick D | Officer: Chief Medical Officer | Buy |
Common Stock | 1,405 |
Jan. 6, 2023 | Cohen Joshua B | Director, Officer: Co-Chief Executive Officer | Buy |
Common Stock | 4,122 |
Jan. 6, 2023 | Frates James M | Officer: Svp & Cfo, Alkermes Plc | Buy |
Common Stock | 1,836 |
Jan. 6, 2023 | Olinger Margaret | Officer: Chief Commercial Officer | Buy |
Common Stock | 1,660 |
Dec. 30, 2022 | Frates James M | Officer: Svp & Cfo, Alkermes Plc | Sell |
Stock Option (Right To Buy) | 5,000 |
Dec. 30, 2022 | Frates James M | Officer: Svp & Cfo, Alkermes Plc | Buy |
Common Stock | 5,000 |
🇺🇸 Congressional Trades
$AMLX trades made by members of the US Congress, Past 120 days
Representative | Committees | Disclosed | Transaction Date | Details | Type | Stock |
![]() Republican, House
|
Agriculture
The Budget
|
Nov. 16, 2022
(35 days after trade)
|
Oct. 12, 2022 |
small
$1,001 - $15,000
|
Buy
|
$AMLX |
![]() Republican, House
|
Agriculture
The Budget
|
Nov. 16, 2022
(35 days after trade)
|
Oct. 12, 2022 |
small
$1,001 - $15,000
|
Buy
|
$AMLX |
Recent Captain Alerts (Last 5)
Alerts are triggered when we detect unusually high conversation volume for $AMLX. Want real-time alerts? Use our Alerts Gadget.
Alert Date | Alert Algorithm | Price At Alert | Recent Price | Conversation Volume Change | Analysts that triggered alert |
---|---|---|---|---|---|
1672928887
[See Details]
|
Analyst A.I. | $35.54 | $39.39 (+10.8%) | +682% | |
1668131651
[See Details]
|
Analyst A.I. | $35.39 | $39.39 (+11.3%) | +341% | |
1666638734
[See Details]
|
Analyst A.I. | $36.64 | $39.39 (+7.5%) | +483% | |
1666027567
[See Details]
|
Analyst A.I. | $36.56 | $39.39 (+7.7%) | +238% | |
1665074891
[See Details]
|
Analyst A.I. | $32.40 | $39.39 (+21.6%) | +217% |
There is not enough conversation volume about this stock
Conviction History
Bullish vs Bearish Conviction over the last 30 days.
This color denotes Market Hours (US/Eastern)
There is not enough conversation volume about this stock
Thread Explorer
Explore popular threads around $AMLX
There are no threads for this stock
Go to Thread Explorer
Chart Explorer
Explore recent charts, graphs, and media
There are no charts for this stock
Latest News
Get the latest breaking news from the community
There is no recent news for this stock
Loading news, hang tight...
Google Search Trends - Past 12 months
Instantly visualize search trends for this specific symbol
Company Profile
Amylyx Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, engages in developing various therapeutics for amyotrophic lateral sclerosis (ALS) and other neurodegenerative diseases. The company's product pipeline includes AMX0035, a dual UPR-Bax apoptosis inhibitor composed of sodium phenylbutyrate and taurursodiol for the treatment of amyotrophic lateral sclerosis. It is also developing AMX0035 for other neurodegenerative diseases. The company was founded in 2013 and is headquartered in Cambridge, Massachusetts.Market Cap Type: Mid